

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

## NICE Technology Appraisal No. 217; Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (donepezil)</li> <li>• Actavis UK (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Aspire Pharma (galantamine, rivastigmine)</li> <li>• Consilient Healthcare (galantamine, memantine)</li> <li>• Dr Reddy's Laboratories (donepezil, rivastigmine, memantine)</li> <li>• Eisai (donepezil)</li> <li>• Lundbeck Ltd (memantine)</li> <li>• Mylan (galantamine, memantine)</li> <li>• Novartis (rivastigmine)</li> <li>• Pfizer (donepezil)</li> <li>• Ranbaxy (donepezil)</li> <li>• Sandoz (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Shire (galantamine)</li> <li>• Teva UK (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Wockhardt UK (donepezil)</li> <li>• Zentiva UK (donepezil, galantamine, memantine)</li> </ul> <p><u>Patient/carers groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Alzheimer's Society</li> <li>• Black Health Agency</li> <li>• Carers UK</li> <li>• Disability Rights UK</li> <li>• Equalities National Council</li> <li>• Innovations in Dementia</li> <li>• Leonard Cheshire Disability</li> <li>• Mental Health Foundation</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Neurological Alliance</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (donepezil)</li> <li>• Actavis UK (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Aspire Pharma (galantamine, rivastigmine)</li> <li>• Consilient Healthcare (galantamine, memantine)</li> <li>• Dr Reddy's Laboratories (donepezil, rivastigmine, memantine)</li> <li>• Eisai (donepezil)</li> <li>• Lundbeck Ltd (memantine)</li> <li>• Mylan (galantamine, memantine)</li> <li>• Novartis (rivastigmine)</li> <li>• Pfizer (donepezil)</li> <li>• Ranbaxy (donepezil)</li> </ul>

<ul style="list-style-type: none"> <li>• Neurological Alliance</li> <li>• Neurosupport</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Directors of Adult Social Services</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Neuropsychiatry Association</li> <li>• College of Mental Health Pharmacy</li> <li>• Dementia Action Alliance</li> <li>• Institute of Neurology</li> <li>• Primary Care Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Psychiatrists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Somerset CCG</li> <li>• NHS South Eastern Hampshire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Sandoz (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Shire (galantamine)</li> <li>• Teva UK (donepezil, galantamine, rivastigmine, memantine)</li> <li>• Wockhardt UK (donepezil)</li> <li>• Zentiva UK (donepezil, galantamine, memantine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Alzheimer’s Research UK</li> <li>• Health Research Authority</li> <li>• Institute for Ageing and Health</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• National Institute for Neurology and Neurosurgery</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> <li>• National Collaborating Centre for Mental Health</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>
--	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

**Definitions:****Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

**Commentators**

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

**Assessment group**

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.